Table 4. Antibiotics given for the treatment of SAB at any time during treatment, including early empirical treatment (N = 5781).
| Antibiotics2 | MRSA | MSSA | ||
| UK (N = 105) | Vietnam/Nepal (N = 14) | UK (N = 402) | Vietnam/Nepal (N = 57) | |
| Flucloxacillin | 19 (18%) | 12 (86%) | 340 (85%) | 46 (81%) |
| Vancomycin | 71 (68%) | 10 (71%)3 | 88 (22%) | 19 (33%) |
| Teicoplanin | 41 (39%) | 0 (0%) | 61 (15%) | 0 (0%) |
| Linezolid | 15 (14%) | 0 (0%) | 12 (3%) | 0 (0%) |
| Rifampin | 22 (21%) | 1 (7%) | 62 (16%) | 3 (5%) |
| Aminoglycoside | 22 (21%) | 2 (14%) | 71 (18%) | 11 (19%) |
| Fucidic acid | 6 (6%) | 0 (0%) | 40 (10%) | 0 (0%) |
| Clindamycin | 3 (3%) | 0 (0%) | 43 (11%) | 0 (0%) |
1
Excludes 15/593 patients known to have been treated but information missing on antibiotics received (n = 10) or susceptibility to methicillin (n = 5, all received flucloxacillin).
2
Of 578 with information on antibiotics received, between 1–4 had missing information on whether they received an antibiotic. Antibiotics other than those listed were given to 81/578 (15%) patients. The most commonly used were a fluoroquinolone (n = 28, 5%) and doxycycline (n = 12, 2%). Daptomycin and tigecycline were used once.
3
The 4 patients not treated with vancomycin either died (n = 1) or were discharged (n = 3) within 24 hours of the positive blood culture.